Search Results - "Avgeris, M"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma by Strati, A., Koutsodontis, G., Papaxoinis, G., Angelidis, I., Zavridou, M., Economopoulou, P., Kotsantis, I., Avgeris, M., Mazel, M., Perisanidis, C., Sasaki, C., Alix-Panabières, C., Lianidou, E., Psyrri, A.

    Published in Annals of oncology (01-08-2017)
    “…Successful application of programmed death 1 (PD1) checkpoint inhibitors in the clinic may ultimately benefit from appropriate patient selection based upon…”
    Get full text
    Journal Article
  2. 2

    The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients by Avgeris, M, Stravodimos, K, Fragoulis, E G, Scorilas, A

    Published in British journal of cancer (25-06-2013)
    “…Background: Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from insignificant and not life…”
    Get full text
    Journal Article
  3. 3

    Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap vaccination in pregnant women in Greece – A cross- sectional study by Papailiou, S., Soldatou, A., Marmarinos, A., Avgeris, M., Papathoma, E., Sindos, M., Georgantzi, S., Rodolakis, Α., Iacovidou, N., Gourgiotis, D., Tsolia, M.

    Published in Vaccine (02-12-2024)
    “…We performed a cross- sectional study in two maternity hospitals in Athens, Greece between 2017 and 2019 assessing seroprevalence and Geometric Mean Titres…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    1139P - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy by Rampias, T., Hoxhallari, L., Avgeris, M., Kanaki, Z., Telios, D., Giotakis, E., Giotakis, I., Scorilas, A., Psyrri, A., Klinakis, A.

    Published in Annals of oncology (01-10-2019)
    “…HRAS is mutated or overexpressed in various cancers. Although numerous studies have demonstrated that HRAS mutations (HRASmut) promote chemoresistance in…”
    Get full text
    Journal Article
  9. 9
  10. 10

    1139PSensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy by Rampias, T, Hoxhallari, L, Avgeris, M, Kanaki, Z, Telios, D, Giotakis, E, Giotakis, I, Scorilas, A, Psyrri, A, Klinakis, A

    Published in Annals of oncology (01-10-2019)
    “…Abstract Background HRAS is mutated or overexpressed in various cancers. Although numerous studies have demonstrated that HRAS mutations (HRASmut) promote…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Abstract A183: Identification of an exon 31-deletion variant of Notch1 receptor with frequent expression in head and neck cancer by Psyrri, Amanda, Pectasides, Eirini, Avgeris, M, Klinakis, Apostolos, Scorilas, Andreas, Sasaki, Clarence, Fountzilas, George, Rampias, Theodoros

    Published in Molecular cancer therapeutics (01-11-2013)
    “…Abstract Introduction: Recently, whole genome sequencing studies revealed that loss of function somatic mutations in NOTCH1 receptor are present in more than…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues by Papachristopoulou, Georgia, Avgeris, Margaritis, Charlaftis, Antonios, Scorilas, Andreas

    Published in Thrombosis and haemostasis (01-01-2011)
    “…Human kallikrein-related peptidase 14 gene (KLK14) is regulated by androgens and progestins. This gene is expressed in the central nervous system and endocrine…”
    Get more information
    Journal Article
  15. 15